

BY FAX/E-MAIL AND CONFIRMATORY COPY BY HAND DELIVERY

July 24, 2014

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023

Dear Sir,

Sub: Voluntary Stoppage of shipments from the Company's Active Pharmaceutical Ingredients (APIs) manufacturing facility situated at Ratlam (Madhya Pradesh) for the US markets

During the recent US FDA inspection at the Company's Active Pharmaceutical Ingredients (APIs) manufacturing facility situated at Ratlam (Madhya Pradesh) the Company has received certain inspection observations in Form 483 from the US FDA.

Consequent to this, the Company has voluntarily decided to temporarily suspend API shipments from this manufacturing facility for the US markets till this issue is addressed.

This voluntarily stoppage of API shipments from the Ratlam manufacturing facility will also have impact on the Company's formulations export business to the US market since the Company's formulations manufacturing units situated at Piparia (Silvassa) and SEZ, Indore (Pithampur) use the APIs manufactured from the Company's Ratlam manufacturing facility for manufacturing formulations for the US market.

The Company is fully committed in resolving this issue at the earliest. The Company is also committed to its philosophy of highest quality in manufacturing, operations, systems, integrity and cGMP culture.

Thanking you

Yours faithfully
For Ipca Laboratories Limited


A. K. Jain
Joint Managing Director

Cc: The Secretary
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051.

Ipca Laboratories Ltd.

www.ipca.com